advertisement

---

Mansberger SL 8

Showing records 1 to 8 | Display all abstracts from Mansberger SL

122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Mansberger SL
Contemporary Clinical Trials 2024; 147: 107730

---

123264 Diagnostic Performance for Detection of Glaucomatous Structural Damage Using Pixelwise Analysis of Retinal Thickness Measurements
Yang H
Investigative Ophthalmology and Visual Science 2024; 65: 17

---

122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Fechtner R
Contemporary Clinical Trials 2024; 147: 107730

---

123264 Diagnostic Performance for Detection of Glaucomatous Structural Damage Using Pixelwise Analysis of Retinal Thickness Measurements
Reynaud J; Sharpe GP
Investigative Ophthalmology and Visual Science 2024; 65: 17

---

122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Lopez K
Contemporary Clinical Trials 2024; 147: 107730

---

123264 Diagnostic Performance for Detection of Glaucomatous Structural Damage Using Pixelwise Analysis of Retinal Thickness Measurements
Jennings D
Investigative Ophthalmology and Visual Science 2024; 65: 17

---

122571 A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study
Hubatsch D
Contemporary Clinical Trials 2024; 147: 107730

---

123264 Diagnostic Performance for Detection of Glaucomatous Structural Damage Using Pixelwise Analysis of Retinal Thickness Measurements
Albert C; Holthausen T; Jiang X; Demirel S; Mansberger SL; Nicolela MT; Gardiner SK; Chauhan BC; Burgoyne CF; Fortune B
Investigative Ophthalmology and Visual Science 2024; 65: 17

---